Amicus Therapeutics (FOLD) Operating Leases (2019 - 2025)
Amicus Therapeutics (FOLD) has disclosed Operating Leases for 7 consecutive years, with $41.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Operating Leases fell 23.48% year-over-year to $41.0 million, compared with a TTM value of $41.0 million through Dec 2025, down 23.48%, and an annual FY2025 reading of $41.0 million, down 23.48% over the prior year.
- Operating Leases was $41.0 million for Q4 2025 at Amicus Therapeutics, down from $42.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $57.2 million in Q4 2023 and bottomed at $41.0 million in Q4 2025.
- Average Operating Leases over 5 years is $48.4 million, with a median of $49.1 million recorded in 2022.
- The sharpest move saw Operating Leases rose 19.58% in 2022, then dropped 23.48% in 2025.
- Year by year, Operating Leases stood at $50.8 million in 2021, then rose by 1.59% to $51.6 million in 2022, then increased by 10.9% to $57.2 million in 2023, then decreased by 6.41% to $53.5 million in 2024, then decreased by 23.48% to $41.0 million in 2025.
- Business Quant data shows Operating Leases for FOLD at $41.0 million in Q4 2025, $42.2 million in Q3 2025, and $43.4 million in Q2 2025.